Calls for papers
-
MAP Pharmaceuticals has announced that it has a meeting scheduled with the FDA during the second quarter of this year to discuss the complete response letter it received for its Levadex inhaled dihydroergotamine application. MAP… Read more . . .
-
Over-the-counter drug manufacturer GSC Products has introduced a horseradish nasal spray marketed as “Sinus Plumber.” The company also developed a capsaicin nasal spray called Sinus Buster that was acquired by Hi-Tech Pharmacal earlier this year… Read more . . .
-
SkyePharma has signed an agreement with RespiVert for a feasibility study to develop an inhaled dry powder formulation for a RespiVert compound, the second DPI project that the two companies have worked on together. Both… Read more . . .
-
The National Institutes of Health (NIH) has awarded Winston Pharmaceuticals a $375,000 Small Business Innovation Research (SBIR) grant to support Phase 1 development of its civamide nasal spray for the treatment of postherpetic neuralgia (PHN)… Read more . . .
-
Shin Nippon Biomedical Laboratories has announced results from a Phase 1 study of its intranasal zolmitriptan formulation (TRZ) for the treatment of migraine headaches. The company is developing several intranasal drugs based on its μco… Read more . . .
-
Merck has issued a statement saying that the company “firmly believes its patent for Nasonex nasal spray is valid and infringed and will vigorously defend its intellectual property rights in a bench trial against Apotex… Read more . . .
-
Copley Scientific will be introducing its new BRS 3000 breath simulator for the testing of metered dose inhalers (MDIs) and dry powder inhalers (DPIs) at RDD 2012. The company previously introduced its BRS 2000 breath… Read more . . .
-
Two dry powder inhalers have been named as finalists in the 2012 Medical Design Excellence Awards sponsored by Medical Device and Diagnostic Industry. Sun Pharmaceutical’s Combitide Starhaler and Novartis’s TOBI Podhaler with Pulmosphere technology are… Read more . . .
-
According to Pearl Therapeutics, the company has produced metered dose inhalers (MDI) with the ability to deliver a 300ng dose of glycopyrrolate (GP) per actuation. Pearl formulated the GP for the nanogram-dose inhalers using the… Read more . . .
-
The British Pharmacopoeial Commission is requesting comment from OINDP manufacturers regarding proposed changes to its inhaled product monographs. The BP has posted a draft document authored by its Inhaled Products Working Party and has asked… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK